Chimerix (NASDAQ:CMRX) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Chimerix (NASDAQ:CMRX) announced its earnings results on Friday. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01, Zacks reports. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million.

Chimerix Stock Performance

CMRX traded up $0.04 during midday trading on Friday, reaching $8.51. 1,899,165 shares of the company were exchanged, compared to its average volume of 2,084,357. The company has a market cap of $764.91 million, a price-to-earnings ratio of -9.05 and a beta of 0.32. Chimerix has a one year low of $0.75 and a one year high of $8.52. The company’s fifty day moving average price is $5.24 and its 200 day moving average price is $2.77.

Insider Activity

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 20,760 shares of company stock worth $91,175 over the last 90 days. 13.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CMRX has been the subject of several recent analyst reports. Wedbush reiterated a “neutral” rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com began coverage on Chimerix in a research note on Saturday, March 15th. They set a “hold” rating on the stock. HC Wainwright restated a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.